Publications by authors named "Alan C Moses"

Claim this Profile
R
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
Simon Heller, Ildiko Lingvay, Steven P Marso, Athena Philis-Tsimikas, Thomas R Pieber, Alan C Moses

Diabetes Obes Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.
Simon Heller, Ildiko Lingvay, Steven P Marso, Athena Philis-Tsimikas, Thomas R Pieber, Alan C Moses

Diabetes Obes Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.
Simon R Heller, John B Buse, Robert Ratner, Elizabeth Seaquist, Lars Bardtrum, Alan C Moses

Diabetes Care· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
Richard E Pratley, Scott S Emerson, Edward Franek, Matthew P Gilbert, Steven P Marso, Alan C Moses

Diabetes Obes Metab· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, Thomas R Pieber, Neil R Poulter, Alan C Moses

Diabetes Obes Metab· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).
Hanne Theilgaard, Inger Mollerup, Ida Carøe Helmark, Lars Endahl, Shawn Hoskin, Alan C Moses

Ther Innov Regul Sci· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus.
Abhinav Sharma, Lauren B Cooper, Mona Fiuzat, Robert J Mentz, João Pedro Ferreira, Alan Charles Moses

JACC Heart Fail· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
William M Steinberg, Michael A Nauck, Bernard Zinman, Gilbert H Daniels, Richard M Bergenstal, Alan C Moses

Pancreas· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.
Alan Charles Moses, Lotte Bjerre Knudsen, Claus Bo Svendsen

Pancreas· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
Lotte Bjerre Knudsen, Niels C Berg Nyborg, Claus Bo Svendsen, Niels Vrang, Alan C Moses

Diabetes Care· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
Steven P Marso, Neil R Poulter, Steven E Nissen, Michael A Nauck, Bernard Zinman, Alan C Moses

Am Heart J· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes prevention: perspectives and actions of one company.
Alan C Moses, Michael Mawby, Anne M Phillips

Am J Prev Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of primary care-relevant treatments for obesity in adults.
Alan C Moses, Yehuda Handelsman, Daniel Einhorn

Ann Intern Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
Laszlo Hegedüs, Alan C Moses, Milan Zdravkovic, Tu Le Thi, Gilbert H Daniels

J Clin Endocrinol Metab· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "The broken pen penalty" (Lakshmanadoss et al.).
Alan C Moses

Diabetes Technol Ther· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Swinnen et al.
Alan C Moses, Christoph Koenen

Diabetes Technol Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Alan C Moses

Endocrinology· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.
Alan C Moses

J Periodontol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?
Alan C Moses

Endocr Dev· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.
Alina Gavrila, William Hsu, Sotirios Tsiodras, John Doweiko, Shiva Gautam, Alan C Moses

Clin Infect Dis· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-Like Growth Factor I in Human Thyroid Tissue: Specific Localization by Immunohistochemistry and In Situ Hybridization.
Rui M. B. Maciel, Edna T. Kimura, Mirian H. Takahaski, Maria-Honorina C. Lopes, Maria-Isabel S. Mesquita, Alan C. Moses

Endocr Pathol· January 1995

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis